Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose: There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly cabazitaxel at 25 mg/m2 (conventional arm A) with cabazitaxel therapeutic drug monitoring (experimental arm B) in mCRPC. The primary objective was to improve the clinical feasibility rate (CFR), defined as the absence of grade 4 neutropenia or thrombocytopenia, any thrombocytopenia with bleeding, febrile neutropenia, severe nonhematologic toxicity, withdrawal for cabazitaxel-related toxicity, or death. A total of 60 patients had to be randomized to detect a difference in CFR of 35% (power 80%, two-sided alpha 10%). Results: A total of 40 patients were randomized to arm A and 33 patients to arm B. CFR was 69.4% in arm A and 64.3% in arm B (P ¼ 0.79). Week-12 PSA response was 38.5% in both arms. A radiological response by RECIST v.1.1 was seen in 3 (9.7%) patients in arm A versus 6 (23.1%) patients in arm B (P ¼ 0.28), disease progression was higher in arm A compared with arm B (61.3% vs. 30.8%, P ¼ 0.05). Median progression-free survival was longer in arm B compared with arm A (9.5 vs. 4.4 months; HR ¼ 0.46; P ¼ 0.005). Median overall survival was higher in arm B compared with arm A (16.2 vs. 7.3 months; HR ¼ 0.33; P < 0.0001). Conclusions: Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.

Cite

CITATION STYLE

APA

Omlin, A., Cathomas, R., von Amsberg, G., Reuter, C., Feyerabend, S., Loidl, W., … Joerger, M. (2023). Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 29(10), 1887–1893. https://doi.org/10.1158/1078-0432.CCR-22-3360

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free